Kymera Therapeutics, Inc.KYMRNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-207.34M
↓ 162% below average
Average (6y)
$-79.13M
Historical baseline
Range
High:$79.03M
Low:$-207.34M
CAGR
+48.6%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-207.34M | -51.0% |
| 2023 | $-137.31M | +11.9% |
| 2022 | $-155.92M | -19.4% |
| 2021 | $-130.54M | -265.2% |
| 2020 | $79.03M | +354.9% |
| 2019 | $17.37M | +190.4% |
| 2018 | $-19.22M | - |